×

[국외논문] (Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients | Who Maintained Virologic Response for One Year After Lamivudine Discontinuation)

[국외논문] (Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization)

[국외논문] (Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis)

[국외논문] (Genetic analysis of HAV strains isolated from patients with acute hepatitis in Korea)

[국외논문] (Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression)

[국외논문] (Levels of hepatitis B virus (HBV) replication during the nonreplicative phase: HBV quantification by real-time PCR in Korea)

[국외논문] (Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy)

[국외논문] (Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy)

[국외논문] (Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B)

[국외논문] (A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B)